Clinical Trials Logo

Clinical Trial Details — Status: Recruiting

Administrative data

NCT number NCT04310319
Other study ID # NL2019WATER
Secondary ID
Status Recruiting
Phase N/A
First received
Last updated
Start date September 7, 2020
Est. completion date October 2021

Study information

Verified date November 2020
Source University Medical Center Groningen
Contact Meijer, Dr.
Phone 003150 361 6161
Email esther.meijer@umcg.nl
Is FDA regulated No
Health authority
Study type Interventional

Clinical Trial Summary

This study evaluates the effect of regulating salt and protein intake on urinevolume in patients with ADPKD treated with a vasopressine V2 receptor antagonist (V2RA). The investigators hypothesize that changing sodium and protein intake will reduce V2RA-induced polyuria.


Description:

Autosomal Dominant Polycystic Kidney Disease (ADPKD) is characterized by the formation of numerous cysts in both kidneys and progressive renal function decline leading to renal replacement therapy (RRT) at a median age of 58 years. The first (and at the moment only) drug to slow down renal function decline, is a vasopressin V2 receptor antagonist (V2RA). This medicament slows renal function decline by 26 to 34%. V2RA also causes aquaresis associated side-effects such as polyuria of >6 liter per day in the majority of patients. These side-effects limit wide spread use among ADPKD-patients. Therefore, there is a need to improve its tolerability. While using a V2RA, urine concentrating ability is strongly diminished. Therefore, urine volume is largely determined by total osmolar excretion. This is a well-known fact in nephrogenic diabetes insipidus, a disease with clear pathophysiological similarities to treatment with a vasopressin V2 receptor antagonist (a defect receptor versus pharmacological blockade). A recent study found osmolar excretion to be associated with urinary volume during V2RA treatment. Whether a change in osmolar load changes polyuria during V2RA has not yet been investigated. The investigators hypothesize that changing sodium and protein intake will reduce polyuria.


Recruitment information / eligibility

Status Recruiting
Enrollment 12
Est. completion date October 2021
Est. primary completion date September 2021
Accepts healthy volunteers No
Gender All
Age group 18 Years and older
Eligibility Inclusion criteria: 1. Diagnosis of ADPKD (ravine criteria/documented by nephrologist) 2. Stable treatment regimen of tolvaptan as part of routine clinical care in the highest dose tolerable (preferably 120 mg daily), with a urine osmolality lower than 250 mosmol/L. 3. Age >= 18 years. 4. eGFR >30 ml/min/1.73m2. 5. Providing informed consent. 6. Compliance to the recommended diet at two consecutive times. Exclusion criteria: 1. Patients who, in the opinion of the investigator may present a safety risk. 2. Patients who are unlikely to adequately comply to the trial's procedures (due for instance to medical conditions likely to require interruption or discontinuation, history of substance abuse or non-compliance). 3. a. Patients taking medication likely to confound endpoint assessments: - lithium in any dosing regimen; - chronic use of systemic corticosteroids in any dosage; - chronic use of any diuretics in any dosing regimen; - daily use of any NSAIDs in any dosing regimen; 3. b. Patients having concomitant illnesses likely to confound endpoint assessments (e.g. diabetes mellitus for which medication is needed or diabetes insipidus). 4. Women who are pregnant or breastfeeding. 5. Patients with a blood pressure over 160/100 mm Hg at baseline.

Study Design


Related Conditions & MeSH terms


Intervention

Dietary Supplement:
Sodiumchloride
Subjects will receive 4 capsules containting 750 NaCl each 2dd, making a total of 6 grams NaCl per day.
Protein
Subjects will receive 2dd 40 ml of a protein beverage containing 0.5 grams of protein per ml, making a total of 40 grams of protein per day.
Placebo comparator (salt)
Subjects will receive 4 placebo capsules (identical to salt capsules) 2dd.
Placebo comparator (protein)
Subjects will receive 2dd 40 ml of placebo beverage (identical to protein beverage).

Locations

Country Name City State
Netherlands UMC Groningen Groningen

Sponsors (1)

Lead Sponsor Collaborator
Esther Meijer

Country where clinical trial is conducted

Netherlands, 

Outcome

Type Measure Description Time frame Safety issue
Primary 24-hour urine volume Change in 24-hour urine volume as percentage, comparing the mean of the volumes collected during baseline with the mean of the two volumes collected at the end of each treatment period. Baseline, week 2, week 4, week 6, week 8.
Secondary Serum copeptin levels Change in serum copeptin levels, comparing copeptin level measured at baseline with copeptin level measured at the end of each treatment period. Baseline, week 2, week 4, week 6, week 8.
Secondary mGFR Change in measured GFR, comparing mGFR measured at baseline with mGFR measured at the end of each treatment period. Baseline, week 2, week 4, week 6, week 8.
Secondary Blood pressure Change in blood pressure, comparing blood pressure measured at baseline with blood pressure measured at the end of each treatment period. Baseline, week 2, week 4, week 6, week 8.
Secondary Quality of life, assesed by using the ADPKD-IS questionnaire. Change in reported quality of life, comparing reported quality of life at baseline to reported quality of life at the end of each treatment period. To assess quality of life, the ADPKD-IS questionnaires will be used. Baseline, week 2, week 4, week 6, week 8.
Secondary Quality of life, assesed by using the NADIQ-questionnaire. Change in reported quality of life, comparing reporter quality of life at baseline to reported quality of life at the end of each treatment period. To assess quality of life, the NADIQ-questionnaires will be used. Baseline, week 2, week 4, week 6, week 8.
See also
  Status Clinical Trial Phase
Completed NCT04363554 - The Kidneys Ability to Concentrate and Dilute Urine in Patients With Autosomal Dominant Polycystic Kidney Disease N/A
Recruiting NCT05521191 - A Study of RGLS8429 in Patients With Autosomal Dominant Polycystic Kidney Disease Phase 1
Completed NCT03687554 - Effect of Venglustat in Patients With Renal Impairment Phase 1
Terminated NCT03523728 - A Medical Research Study Designed to Determine if Venglustat Can be a Future Treatment for ADPKD Patients Phase 2/Phase 3
Completed NCT00565097 - Lanreotide as Treatment of Polycystic Livers Phase 2/Phase 3
Completed NCT00410007 - The Effect of High and Low Sodium Intake on Urinary Aquaporin-2 in Autosomal Dominant Polycystic Kidney Disease N/A
Completed NCT02251275 - Long Term Safety of Immediate-release Tolvaptan in Subjects With Autosomal Dominant Polycystic Kidney Disease Phase 3
Completed NCT01559363 - A Safety, Pharmacokinetic & Dose-Escalation Study of KD019 in Subjects With Autosomal Dominant Polycystic Kidney Disease Phase 1/Phase 2
Completed NCT02903511 - Feasibility Study of Metformin Therapy in ADPKD Phase 2
Completed NCT00456365 - Effect of Statin Therapy on Disease Progression in Autosomal Dominant Polycystic Kidney Disease (ADPKD) Phase 3
Recruiting NCT05510115 - Feasibility of Study of Empagliflozin in Patients With Autosomal Dominant Polycystic Kidney Disease Phase 2
Completed NCT02494141 - Curcumin Therapy to Treat Vascular Dysfunction in Children and Young Adults With ADPKD Phase 4
Completed NCT04407481 - PErfusioN, OxyGen ConsUmptIon and ENergetics in ADPKD (PENGUIN)
Completed NCT02847624 - Post-Marketing Surveillance Study of Tolvaptan in Patients With ADPKD
Completed NCT03342742 - Daily Caloric Restriction and Intermittent Fasting in Overweight and Obese Adults With Autosomal Dominant Polycystic Kidney Disease N/A
Completed NCT02656017 - Metformin as a Novel Therapy for Autosomal Dominant Polycystic Kidney Disease Phase 2
Completed NCT04023214 - The Role of Endothelial Dysfunction in Adult Polycystic Kidney Disease
Terminated NCT01589705 - The Relation Between Uric Acid Level and Endothelial Dysfunction in Patients With Polycystic Kidney Disease N/A
Completed NCT00426153 - Octreotide in Severe Polycystic Liver Disease Phase 2/Phase 3
Completed NCT04534985 - Time Restricted Feeding in Autosomal Dominant Polycystic Kidney Disease N/A